Cytyc Forms Advisory Board to Evaluate and Develop New Clinical Technologies.Business Editors/Health/Medical Writers BOXBOROUGH, Mass.--(BUSINESS WIRE)--May 13, 2004 Cytyc Corporation (Nasdaq: CYTC) today announced the formation of a Clinical Technologies Advisory Board (CTAB CTAB Clear to auscultation bilaterally, see there ). The CTAB will provide expert and candid advice on the merits on the merits adj. referring to a judgment, decision or ruling of a court based upon the facts presented in evidence and the law applied to that evidence. A judge decides a case "on the merits" when he/she bases the decision on the fundamental issues and considers and clinical utility of new diagnostic and therapeutic technologies. The advisors will also help evaluate and further develop Cytyc's existing product line and provide guidance on research programs underway with Cytyc's academic partners. The board is comprised of distinguished thought leaders in the field of women's health Women's Health Definition Women's health is the effect of gender on disease and health that encompasses a broad range of biological and psychosocial issues. , representing a range of medical specialties Medical Specialties See also anatomy; disease and illness; drugs; health; remedies; surgery. adenography the science of the description of glands. — adenographic, adj. including obstetrics and gynecology obstetrics and gynecology Medical and surgical specialty concerned with the management of pregnancy and childbirth and with the health of the female reproductive system. , gynecologic oncology Gynecologic oncology is a specialized field of medicine that focuses only on cancers of the female reproductive system, notably ovarian cancer, cervical cancer, endometrial cancer and vulvar cancer. , pathology, molecular microbiology, immunology, and epidemiology. "The creation of this advisory board reinforces our commitment to develop and expand our business by identifying the most promising technologies that fit our strategic and tactical objectives and leverage our core competencies," said Patrick J. Sullivan, Cytyc's chairman, chief executive officer and president. "The breadth of scientific expertise represented by this panel will provide us wise counsel regarding a wide range of women's health innovations."
The membership of the Clinical Technology Advisory Board includes:
Jeff Boyd, Ph.D.
Director, Gynecology and Breast Research Laboratory
Memorial Sloan-Kettering Cancer Center, New York
Phil Darney, M.D., MSc
Professor, Obstetrics, Gynecology, and Reproductive Sciences,
University of California, San Francisco; Chief of Obstetrics and
Gynecology, San Francisco General Hospital
Peter M. Howley, M.D.
Chair, Department of Pathology, Harvard Medical School
Shattuck Professor of Anatomical Pathology, Harvard Medical School
Keith B. Isaacson, M.D.
Associate Professor, Obstetrics, Gynecology and Reproductive
Biology, Harvard Medical School; Medical Director, Minimally
Invasive Gynecologic Surgery Unit, Newton-Wellesley Hospital
Thomas F. Purdon, M.D., FACOG
Professor, Clinical Obstetrics and Gynecology, and Vice-Chair,
Department of Obstetrics and Gynecology, University of Arizona
College of Medicine, Tucson
John T. Repke, M.D.
Professor and Chair, Obstetrics and Gynecology, Penn State
University College of Medicine; Obstetrician Gynecologist in
Chief, Milton S. Hershey Medical Center, Hershey, Pennsylvania
Lawrence N. Shulman, M.D.
Associate Professor of Medicine, Harvard Medical School
Chief Medical Officer and Senior Vice President for Medical
Affairs, Dana-Farber Cancer Institute; Physician, Brigham and
Women's Hospital
Elizabeth A. Stewart, M.D.
Associate Professor, Obstetrics, Gynecology and Reproductive
Medicine, Harvard Medical School; Clinical Director, Center for
Uterine Fibroids, Brigham and Women's Hospital
Jonathan Zenilman, M.D.
Professor, Division of Infectious Diseases, Johns Hopkins
University School of Medicine; Chief, Infectious Diseases Service,
Johns Hopkins Bayview Medical Center
(Participation by individual advisors does not constitute or imply
endorsement by the institutions and organizations with which they
are affiliated.)
Cytyc Corporation is a leading medical device company that designs, develops, manufactures, and markets innovative and clinically effective products primarily focused on women's health. Cytyc products cover a range of women's health applications, including cervical cancer Cervical Cancer Definition Cervical cancer is a disease in which the cells of the cervix become abnormal and start to grow uncontrollably, forming tumors. screening, breast cancer risk assessment, and treatment of excessive menstrual bleeding. The ThinPrep(R) System is the most widely used method for cervical cancer screening in the United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. . The ThinPrep System consists of the ThinPrep(R) 2000 Processor, ThinPrep(R) 3000 Processor, ThinPrep(R) Imaging System, and related reagents, filters, and other supplies. The ThinPrep System also provides the platform from which the Company has launched its expansion into breast cancer risk assessment with the FirstCyte(R) Breast Test. Cytyc Surgical Products, a wholly owned subsidiary Wholly Owned Subsidiary A subsidiary whose parent company owns 100% of its common stock. Notes: In other words, the parent company owns the company outright and there are no minority owners. of Cytyc Corporation, manufactures and markets the NovaSure(R) Impedance Controlled Endometrial Ablation Endometrial ablation is a medical procedure that is used to remove (ablate) or destroy the endometrial lining of a woman's uterus. This technique is most often employed for women who suffer from excessive or prolonged bleeding during their menstrual cycle but can not or do not wish System, or the NovaSure(R) System, an innovative endometrial ablation device to treat menorrhagia menorrhagia /men·or·rha·gia/ (men?ah-ra´jah) hypermenorrhea. men·or·rha·gia n. See hypermenorrhea. , or excessive menstrual bleeding. Cytyc is traded on The Nasdaq Stock Market Nasdaq stock market The first electronic stock market listing over 5000 companies. The Nasdaq stock market comprises two separate markets, namely the Nasdaq National Market, which trades large, active securities and the Nasdaq Smallcap Market that trades emerging growth companies. under the symbol CYTC. Cytyc, ThinPrep, NovaSure, and FirstCyte are registered trademarks of Cytyc Corporation. Forward-looking statements in this press release are made pursuant to the provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that statements in this press release which are not strictly historical statements, including, without limitation, statements relating to the Company's financial condition, operating results and future economic performance, and management's expectations regarding future growth opportunities, product acceptance and business strategy, constitute forward-looking statements. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from those statements. Risks and uncertainties include, among others, dependence on key personnel and proprietary technology, uncertainty of product development efforts, product acceptance, management of growth, risks associated with litigation An action brought in court to enforce a particular right. The act or process of bringing a lawsuit in and of itself; a judicial contest; any dispute. When a person begins a civil lawsuit, the person enters into a process called litigation. and the effective integration of acquired businesses and technologies, competition and competitive pricing pressures, risks associated with the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. regulatory approval processes and any healthcare reimbursement policies, and other risks detailed in the Company's filings with the Securities and Exchange Commission, including under the heading "Certain Factors Which May Affect Future Results" in its 2003 Annual Report on Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. and its most recent Quarterly Report on Form 10-Q Form 10-Q See 10-Q. filed with the Commission. The Company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they were made. The Company disclaims any obligation to publicly update or revise any such statements to reflect any change in Company expectations or events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion